Synlogic, Inc. - SYBX STOCK NEWS

Synlogic, Inc. (Nasdaq: SYBX) has announced its 2022 Annual General Meeting of Stockholders, scheduled for June 9, 2022, at 9:00 A.M. ET, to be held virtually. Stockholders of record as of April 12, 2022, can participate by accessing the meeting center. The company encourages all stockholders to vote and submit their proxy in advance. Synlogic focuses on developing medicines for metabolic and immunological diseases through synthetic biology, with pipeline candidates targeting conditions like phenylketonuria and inflammatory bowel disease, supported by collaborations with Roche and Ginkgo Bioworks.

Synlogic, a clinical-stage biotechnology company, received a positive opinion from the European Medicines Agency (EMA) for orphan designation of SYNB1618, aimed at treating phenylketonuria (PKU). This builds on the U.S. FDA's previous granting of both Orphan Drug and Fast Track designations for SYNB1618. The EMA designation offers financial and regulatory incentives, including up to 10 years of marketing exclusivity in the EU. Synlogic plans to advance SYNB1618 into a registrational trial in 2023.

Synlogic, Inc. (Nasdaq: SYBX) announced its Q1 2022 financial results, reporting a net loss of $15.7 million or $0.22 per share. The company has $120.5 million in cash, supporting operations into 2024. Progress includes Phase 3 readiness for its phenylketonuria (PKU) program, with key data readouts expected in H2 2022. Additional milestones include the initiation of the Phase 3 trial in H1 2023 and sharing of Phase 1 data for SYNB1353. Synlogic continues collaborations with Ginkgo Bioworks and Roche for innovative treatments in metabolic diseases.

Synlogic, Inc. (Nasdaq: SYBX) announced it will release its Q1 2022 financial results on May 12, 2022, before market opening. Following the release, a conference call is scheduled at 8:30 am ET to discuss the results and business updates. Investors can join via telephone or webcast. Synlogic focuses on developing medicines for metabolic and immunological diseases using synthetic biology, with promising drugs in its pipeline targeting conditions like phenylketonuria and inflammatory bowel disease.

Synlogic, Inc. (Nasdaq: SYBX), a biotechnology company specializing in synthetic biology, announced upcoming presentations of data from its phenylketonuria (PKU) program. Presentations include two posters at the Genetic Metabolic Dieticians International Conference from May 5-7, 2022, and a data presentation at the Garrod Symposium on May 13, 2022. Synlogic's lead program, SYNB1618, aims to provide effective treatment options for PKU patients, with plans for a pivotal Phase 3 study in the second half of 2022.

Synlogic, Inc. (Nasdaq: SYBX) announced its presentations at the 2022 SEED conference, taking place May 2-5 in Arlington, VA. These include an oral presentation detailing the progress of Synthetic Biotic drug candidates for metabolic diseases such as phenylketonuria (PKU) and homocystinuria (HCU). The conference will showcase preclinical and clinical data across five programs. With a focus on synthetic biology, Synlogic aims to address significant medical needs through innovative biotherapeutics.

Scorpion Therapeutics has appointed Dr. Saurabh Saha to its Board of Directors. Dr. Saha, CEO of Centessa Pharmaceuticals, has over 20 years of experience in biopharmaceutical research. This strategic appointment aligns with Scorpion's Precision Oncology 2.0 strategy, aiming to enhance cancer treatment development. Dr. Saha's expertise is expected to be pivotal as the company prepares for investigational new drug applications for its lead programs in the upcoming year.

Synlogic, a clinical-stage biotechnology company, announced that it will present data from its phenylketonuria (PKU) and homocystinuria (HCU) programs at the SIMD 43rd Annual Meeting from April 10-13, 2022, in Orlando, Florida. Two posters will highlight investigational drug candidates SYNB1353 for HCU and SYNB1618/SYNB1934 for PKU. These include preclinical findings showing SYNB1353's efficacy in lowering homocysteine levels, and clinical data from the SynPheny-1 study on phenylalanine metabolism. The posters will be available on Synlogic's website starting April 11, 2022.

Synlogic, a clinical-stage biotechnology company, reported financial results for Q4 and the full year of 2021, highlighting a cash position of $136.6 million that supports operations into 2024. The company is advancing its Phenylketonuria (PKU) program towards a Phase 3 trial initiation in H2 2022. Synlogic achieved proof of concept for its lead drug SYNB1618 in the Phase 2 trial, with additional data expected in H1 2022. For the year, revenue was $1.8 million, with a net loss of $60.6 million, improving from a $59.2 million loss in 2020.